These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21176719)

  • 21. Desvenlafaxine for depression.
    Med Lett Drugs Ther; 2008 May; 50(1286):37-9. PubMed ID: 18487957
    [No Abstract]   [Full Text] [Related]  

  • 22. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.
    Thase ME; Fayyad R; Cheng RF; Guico-Pabia CJ; Sporn J; Boucher M; Tourian KA
    Curr Med Res Opin; 2015 Apr; 31(4):809-20. PubMed ID: 25758058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correction of venlafaxine- and duloxetine-induced transaminase elevations with desvenlafaxine in a patient with Gilbert's syndrome.
    Feinberg SS
    CNS Spectr; 2010 Jan; 15(1):53-5. PubMed ID: 20394185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Desvenlafaxine in the treatment of major depressive disorder.
    Pae CU
    Expert Opin Pharmacother; 2011 Dec; 12(18):2923-8. PubMed ID: 22098230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.
    Gallagher JC; Strzinek RA; Cheng RF; Ausmanas MK; Astl D; Seljan P
    J Womens Health (Larchmt); 2012 Feb; 21(2):188-98. PubMed ID: 22032759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.
    Clayton AH; Tourian KA; Focht K; Hwang E; Cheng RF; Thase ME
    J Clin Psychiatry; 2015 May; 76(5):562-9. PubMed ID: 25375652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.
    Liebowitz MR; Tourian KA
    Prim Care Companion J Clin Psychiatry; 2010; 12(3):. PubMed ID: 20944767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
    Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
    Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.
    Nichols AI; Fatato P; Shenouda M; Paul J; Isler JA; Pedersen RD; Jiang Q; Ahmed S; Patroneva A
    J Clin Pharmacol; 2009 Feb; 49(2):219-28. PubMed ID: 19001559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desvenlafaxine extended release.
    Yang LP; Plosker GL
    CNS Drugs; 2008; 22(12):1061-9. PubMed ID: 18998743
    [No Abstract]   [Full Text] [Related]  

  • 33. [The enantioselective pharmacokinetic study of desvenlafaxine sustained release tablet in Chinese healthy male volunteers after oral administration].
    Chen YX; Du JB; Zhang YF; Chen XY; Zhong DF
    Yao Xue Xue Bao; 2015 Apr; 50(4):486-91. PubMed ID: 26223133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.
    Findling RL; Groark J; Tourian KA; Ramaker SA; Chiles D; Yang L; Nichols AI
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):909-921. PubMed ID: 27428303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper.
    Sampogna G; Caraci F; Carmassi C; Dell'Osso B; Ferrari S; Martinotti G; Sani G; Serafini G; Signorelli MS; Fiorillo A
    Expert Opin Pharmacother; 2023; 24(14):1511-1525. PubMed ID: 37450377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Desvenlafaxine in the treatment of major depression: an updated overview.
    Norman TR; Olver JS
    Expert Opin Pharmacother; 2021 Jun; 22(9):1087-1097. PubMed ID: 33706624
    [No Abstract]   [Full Text] [Related]  

  • 38. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
    Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
    Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
    Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
    Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of renal impairment on the pharmacokinetics of exenatide.
    Linnebjerg H; Kothare PA; Park S; Mace K; Reddy S; Mitchell M; Lins R
    Br J Clin Pharmacol; 2007 Sep; 64(3):317-27. PubMed ID: 17425627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.